BLISSGVS vs PPLPHARMA: Stock Comparison

Bliss GVS Pharma Limited vs Piramal Pharma Limited

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 10 of 13 scored metrics and PPLPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹25,562 Cr vs ₹4,916 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-78.29x vs 37.76x
P/B Ratio
PPLPHARMA has a lower P/B
3.12x vs 4.09x
EPS
BLISSGVS has higher earnings per share
₹11.99 vs ₹-2.45
Dividend Yield
BLISSGVS has a higher dividend yield
0.19% vs 0.08%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs -0.1%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs 0%
Qtr Sales Growth
BLISSGVS has stronger quarterly sales growth
13% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSPPLPHARMA
Live Price₹527.1₹192.05
Day Change0.68%5.95%
Volume3.93 L1.52 Cr
52-Week High₹553₹210.5
52-Week Low₹118₹132.3
Distance from 52W High-4.68%-8.76%

Valuation

MetricBLISSGVSPPLPHARMA
Market Cap₹4,916 Cr₹25,562 Cr
P/E Ratio37.76x-78.29x
P/B Ratio4.09x3.12x
EPS₹11.99₹-2.45
Book Value₹107.21₹64.78
Dividend Yield0.19%0.08%

Growth

MetricBLISSGVSPPLPHARMA
Revenue Growth (TTM YoY)29.8%-0.1%
EPS Growth (TTM YoY)124.7%0%
Qtr Sales Growth13%-0.08%
Qtr Profit Growth108%-25%

Profitability & Leverage

MetricBLISSGVSPPLPHARMA
ROE0%-3.83%
ROCE11.7%2.52%
Net Margin13.93%-3.68%
Operating Margin12.82%10.4%
Debt to Equity1.77x0.7x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBLISSGVSPPLPHARMA
Promoter Holding35.01% 0.35 pp34.8% 0.06 pp
FII Holding8.07% 2.38 pp12.52% 17.66 pp
DII Holding9.47% 4.43 pp14.57% 1.04 pp
Public Holding47.45% 1.7 pp37.63% 18.62 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.